Cargando…

Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine

Refractory chronic migraine is a disabling disorder impacting quality of life. BOTOX(®) (Onabotulinumtoxin A) is approved as a prophylactic treatment of chronic migraine in patients unresponsive to at least three prior preventive treatments. The objective of this study was to determine the prophylac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ion, Ioana, Renard, Dimitri, Le Floch, Anne, De Verdal, Marie, Bouly, Stephane, Wacongne, Anne, Lozza, Alessandro, Castelnovo, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024863/ https://www.ncbi.nlm.nih.gov/pubmed/29857565 http://dx.doi.org/10.3390/toxins10060221

Ejemplares similares

Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin(®))
por: Dressler, Dirk, et al.
Publicado: (2013)

Profile of Xeomin(®) (incobotulinumtoxinA) for the treatment of blepharospasm
por: Park, Juwan, et al.
Publicado: (2011)

Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study
por: Hefter, Harald, et al.
Publicado: (2020)

Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins
por: Hefter, Harald, et al.
Publicado: (2021)

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm
por: Truong, Daniel D., et al.
Publicado: (2013)

A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins
por: Jimenez-Shahed, Joohi
Publicado: (2012)

A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia
por: Evidente, Virgilio Gerald H., et al.
Publicado: (2013)

The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
por: Morgante, Francesca, et al.
Publicado: (2019)

Trigeminal neuralgia: IncobotulinumtoxinA (Xeomin), can it decrease the pharmacological intervention? (A case series)
por: Hosseini, Meghdad, et al.
Publicado: (2023)

Thalamic Lesions: A Radiological Review
por: Renard, Dimitri, et al.
Publicado: (2014)

Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®
por: Frevert, Jürgen
Publicado: (2012)

AbobotulinumtoxinA (Dysport(®)), OnabotulinumtoxinA (Botox(®)), and IncobotulinumtoxinA (Xeomin(®)) Neurotoxin Content and Potential Implications for Duration of Response in Patients
por: Field, Malgorzata, et al.
Publicado: (2018)

Effects of Ultrasound-Guided Administration of Botulinum Toxin (IncobotulinumtoxinA) in Patients with Lateral Epicondylitis
por: Galván Ruiz, Antonio, et al.
Publicado: (2019)

Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia
por: Fernandez, Hubert H., et al.
Publicado: (2013)

Effectiveness and Safety of Intracavernosal IncobotulinumtoxinA (Xeomin(®)) 100 U as an Add-on Therapy to Standard Pharmacological Treatment for Difficult-to-Treat Erectile Dysfunction: A Case Series
por: Giuliano, Francois, et al.
Publicado: (2022)

Correction: Field, M. et al. AbobotulinumtoxinA (Dysport(®)), OnabotulinumtoxinA (Botox(®)), and IncobotulinumtoxinA (Xeomin(®)) Neurotoxin Content and Potential Implications for Duration of Response in Patients
por: Field, Malgorzata, et al.
Publicado: (2019)

Functional influence of botulinum neurotoxin type A treatment (Xeomin®) of multifocal upper and lower limb spasticity on chronic hemiparetic gait
por: Falso, Maurizio, et al.
Publicado: (2012)

Xeomin(®), a Commercial Formulation of Botulinum Neurotoxin Type A, Promotes Regeneration in a Preclinical Model of Spinal Cord Injury
por: Mastrorilli, Valentina, et al.
Publicado: (2023)

EHMTI-0037. Botulinum A toxin for treatment of chronic migraine
por: Grazzi, L, et al.
Publicado: (2014)

There is Value in Anecdotal Reports of Relief from Migraine with Botulinum Toxin
por: Winett, Bill
Publicado: (2009)

IncobotulinumtoxinA for Post-stroke Upper Limb Spasticity in Neutralizing Antibody-positive Patients after Botulinum Toxin Therapy: A Report of Two Cases
por: Masakado, Yoshihisa, et al.
Publicado: (2022)

Efficacy of Intra-Articular Injection of Botulinum Toxin Type A (IncobotulinumtoxinA) in Temporomandibular Joint Osteoarthritis: A Three-Arm Controlled Trial in Rats
por: Béret, Marie, et al.
Publicado: (2023)

Postsurgical Refractory Gastroparesis: Response to Botulinum Toxin Therapy
por: Sarvepalli, Deepika, et al.
Publicado: (2020)

Botulinum Toxin a Valuable Prophylactic Agent for Migraines and a Possible Future Option for the Prevention of Hormonal Variations-Triggered Migraines
por: Dima, Lorena, et al.
Publicado: (2019)

Conversion Ratio between Botox(®), Dysport(®), and Xeomin(®) in Clinical Practice
por: Scaglione, Francesco
Publicado: (2016)

Botulinum Toxin Type A Therapy in Migraine: Preclinical and Clinical Trials
por: Shao, Yu-Feng, et al.
Publicado: (2013)

Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine
por: Herd, Clare P, et al.
Publicado: (2019)

Humanistic, Utilization, and Cost Outcomes Associated With the Use of Botulinum Toxin for Treatment of Refractory Migraine Headaches in a Managed Care Organization
por: Mitchell, Matthew P., et al.
Publicado: (2008)

Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine
por: Robertson, Carrie E, et al.
Publicado: (2012)

EHMTI-0394. Predictive parameters for the effect of botulinum toxin infiltrations in chronic migraine
por: Bergmans, BA, et al.
Publicado: (2014)

P042. Mechanism of action and clinical evidence of botulinum toxin in chronic migraine
por: Franco, Giovanni, et al.
Publicado: (2015)

O048. Chronic migraine, cluster headache or both? The suggestion of botulinum toxin
por: Ripa, Patrizia, et al.
Publicado: (2015)

The Development of Psychiatric Illness and Chemoprophylaxis of Botulinum Toxin in Migraine: A Narrative Review
por: Dhengare, Ayushi S, et al.
Publicado: (2022)

Comparing soleus injections and gastrocnemius injections of botulinum toxin for treating adult spastic foot drop: a monocentric observational study
por: Hefter, Harald, et al.
Publicado: (2021)

Endoscopic Botulinum Toxin Injection for Refractory Enuresis Based on Urodynamic Assessment
por: Jung, Gyoohwan, et al.
Publicado: (2021)

BOTULINUM TOXIN
por: Nigam, P K, et al.
Publicado: (2010)

Injecting botulinum toxin into the treatment of blepharospasm
por: Popescu, Marius Nicolae, et al.
Publicado: (2018)

Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study
por: Barrientos, Nelson, et al.
Publicado: (2003)

Botulinum Toxin—A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches
por: Kępczyńska, Katarzyna, et al.
Publicado: (2022)

Impact of delaying botulinum toxin treatment in patients with migraine during the COVID-19 pandemic
por: Nascimento, Henrique, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i4f41947jfj449p2omo4r2dg6v